Low-dose naltrexone for disease prevention and quality of life
http://www.opioids.com/naltrexone/lowdosenaltrexone.pdf
Norman Brown a,*, Jaak Panksepp b
a Department of Humanities and Social Sciences, Embry-Riddle Aeronautical University, Daytona Beach, FL 32114, United States
b Department of VCAPP, College of Veterinary Medicine, Washington State University, P.O. Box 646520, Pullman, WA 99164-6520, United States
a r t i c l e i n f o
Article history:
Received 3 June 2008
Accepted 12 June 2008
s u m m a r y
The use of low-dose naltrexone (LDN) for the treatment and prophylaxis of various bodily disorders is
discussed. Accumulating evidence suggests that LDN can promote health supporting immune-modulation
which may reduce various oncogenic and inflammatory autoimmune processes. Since LDN can
upregulate endogenous opioid activity, it may also have a role in promoting stress resilience, exercise,
social bonding, and emotional well-being, as well as amelioration of psychiatric problems such a autism
and depression. It is proposed that LDN can be used effectively as a buffer for a large variety of bodily and
mental ailments through its ability to beneficially modulate both the immune system and the brain neurochemistries
that regulate positive affect.
2008 Published by Elsevier Ltd.
Threaded Mode